8-K filing — Outlook Therapeutics, Inc. (OTLK)
Filed: 2026-09-18 AccNo: 0001104659-26-108952 Size: 186 KB Item 8.01: Other Events
Stocks · News reference
Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call
Outlook Therapeutics (NASDAQ:OTLK) released third-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.
Outlook Therapeutics Announces Appointment Of Kevin Lundquist As CFO Effective September 1
BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target
BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $4 price target.